Tag: GlobeNewswire

Strategic acquisition adds two Philippines sites and deep BPO expertise across healthcare, financial services, legal services, e-commerce and other verticals

ST. PETERSBURG, Fla., Nov. 02, 2026 (GLOBE NEWSWIRE) — The Office Gurus (TOG), the Contact Centers segment of Superior Group of Companies, Inc. (NASDAQ: SGC), today announced the acquisition of Select VoiceCom (SVC), a Philippines-based business process outsourcing (BPO) provider with delivery centers in Cebu City and Davao.

The acquisition establishes TOG’s direct operating presence in the Philippines, expands its global delivery footprint, and advances its Experience Process Outsourcing (EPO) strategy.

“Select VoiceCom has built a terrific business over 18 years, with a talented team, strong client relationships and a people-first culture that aligns with our own,” said Dominic Leide, President of The Office Gurus. “SVC gives us an outstanding foundation in the Philippines and new ways to create value for our clients worldwide. We are excited to welcome SVC into the Guru family.”

SVC’s founding leaders, Mark Shapiro and Trevor Michael, will remain involved to support continuity for clients and employees. Its operations leadership will continue to oversee the Cebu City and Davao sites within TOG’s global operations structure. The combined organization will benefit from TOG’s EPO approach and GuruSuite iX AI-enabled technology ecosystem to enhance agent performance, quality assurance, training, analytics and customer interaction automation.

“Joining The Office Gurus allows us to build upon the culture, relationships and local leadership that made SVC successful, supported by TOG’s global reach, technology and resources,” said Mark Shapiro, Co-Founder of Select VoiceCom. “We are excited about what this means for our people and clients.”

Cross Keys Capital served as exclusive financial advisor and Hill Ward Henderson and Quisumbing Torres (member firm of Baker & McKenzie International) served as legal counsel to SGC and TOG in connection with the transaction.

Disclosure Regarding Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential,” or “plan” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements in this press release include statements regarding the Company’s capital allocation strategy and growth.  Such forward-looking statements are subject to certain risks and uncertainties that may materially adversely affect the anticipated results. Such risks and uncertainties include, but are not limited to, the factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those risks described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 entitled “Risk Factors” and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements made herein and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and we disclaim any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as may be required by law.

About The Office Gurus

The Office Gurus is a global provider of customer experience and business process outsourcing solutions, combining engaged people, operational expertise and AI-enabled technology to help organizations improve customer experience and business performance.

About Superior Group of Companies, Inc. (SGC)

Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers (operating as The Office Gurus (TOG)), each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. We are committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit www.superiorgroupofcompanies.com.

Contact:
Investor Relations
Investors@superiorgroupofcompanies.com

NVIDIA B300 GPU Leasing Operations Establish Foundation for Recurring Revenue as Company Advances Proposed Real Estate Divestiture, Expected to Reduce Legacy Operating Costs, Strengthen Balance Sheet and Support Long-Term Growth

Proposed Ocean Power Technologies Collaboration Expands Potential AI Infrastructure Applications Through Offshore, Renewable-Powered Computing

CELEBRATION, FL, Nov. 02, 2026 (GLOBE NEWSWIRE) — Stratum Holdings Corp. (NASDAQ: SRTM) (“Stratum”) today issued a letter to shareholders from Chief Executive Officer Nicholas H. Adler outlining the Company’s progress in executing its strategic transformation, including its NVIDIA B300 GPU leasing business, proposed divestiture of legacy real estate operations and development of new AI infrastructure opportunities.

Key Strategic Highlights

• AI Infrastructure Revenue: Acquired NVIDIA B300 GPUs and placed them under a long-term leasing arrangement intended to generate recurring revenue.
• Balance Sheet Optimization: Advancing the proposed divestiture of legacy real estate businesses, which is expected to remove certain liabilities and reduce operating expenses and working-capital requirements, subject to completion. The Company expects to enter into a definitive sale agreement by year-end 2026.
• Recurring Revenue Opportunity: Pursuing additional GPU leasing arrangements to expand the Company’s high-performance computing asset base and potential recurring revenue.
• Strategic Expansion: Entered into a non-binding letter of intent with Ocean Power Technologies to explore offshore, renewable-powered AI computing infrastructure.
• Profitability Goal: Maintaining its goal of achieving profitability in 2027 through revenue growth, operating efficiencies and disciplined capital allocation.

Dear Fellow Shareholders,

Over the past several weeks, Stratum Holdings has taken important steps toward transforming our Company into a focused AI infrastructure business. Our strategy is centered on building a platform that provides high-performance computing capacity to support the growing demands of artificial intelligence, while simplifying our corporate structure and pursuing opportunities to expand the applications of our technology.

Our recent announcements reflect a deliberate approach to this transformation. We have acquired next-generation NVIDIA B300 GPUs and placed them under a long-term lease intended to generate recurring revenue. We have entered into a letter of intent for the proposed sale of our legacy real estate operations, which we believe will allow us to concentrate our resources on AI infrastructure. Most recently, we announced a proposed strategic collaboration with Ocean Power Technologies to explore renewable-powered offshore computing applications.

Importantly, we are now focused on advancing these initiatives toward their next stages of execution, including working toward definitive agreements for both the proposed real estate divestiture and our strategic collaboration with Ocean Power Technologies.

Establishing Our AI Infrastructure Business

On October 1, 2026, we announced the acquisition of next-generation NVIDIA B300 GPUs, representing an important initial step in building our AI infrastructure platform.

These GPUs are designed to support demanding artificial intelligence workloads, including model training and inference. By placing the acquired GPUs under a 32-month non-cancelable lease, we have established an initial asset base intended to generate recurring revenue and support the development of our GPU leasing business.

We believe this asset-backed approach provides a foundation from which to pursue additional opportunities in high-performance computing. Our strategy is to participate in the underlying infrastructure required to support AI workloads.

As we move forward, our focus will be on evaluating opportunities to expand our GPU capacity, establish additional commercial relationships and build a scalable business around the ownership and leasing of high-performance computing assets. We believe expanding our portfolio of leased GPU assets could be an important part of our long-term growth strategy, as we seek opportunities to increase recurring revenue.

Simplifying Our Business and Strengthening Our Financial Position

Building a focused AI infrastructure company also requires making strategic decisions about where we allocate capital and management resources. We believe our transformation is progressing in the right direction, with recent developments reflecting tangible steps toward simplifying our business and focusing our operations on our long-term growth strategy.

On October 19, 2026, we announced that we had entered into a non-binding letter of intent for the proposed sale of substantially all assets of our legacy real estate businesses, including brokerage, franchising, property management, mortgage, title and related operations.

If completed, the proposed transaction is expected to strengthen our financial position by removing certain liabilities, operating costs and working-capital requirements associated with these legacy businesses, including trade payables and other specified liabilities to be assumed by the proposed buyer. This would allow us to direct greater financial and management resources toward executing our AI infrastructure strategy. We believe the divestiture represents an important step toward our goal of achieving profitability in 2027.

We continue to make progress in discussions with the proposed buyer. While the transaction remains subject to the negotiation and execution of definitive documentation and other customary conditions, we are encouraged by the progress to date and believe the anticipated divestiture would represent a significant milestone in our transformation.

Expanding the Potential Applications of Our Computing Infrastructure

Beyond building our initial GPU asset base, we are exploring opportunities to deploy high-performance computing capacity in environments where traditional data center infrastructure may be impractical or costly.

Towards that end, on October 26, 2026, we announced a non-binding letter of intent with Ocean Power Technologies, Inc. (“OPT”) to explore the development of offshore, renewable-powered data center assets.

The proposed collaboration would combine OPT’s PowerBuoy® platforms, which are backed by more than 60 issued patents worldwide, and associated technology with Stratum’s NVIDIA B300 GPUs and integration expertise to evaluate the feasibility of supporting AI inference and other computing workloads in offshore environments.

Under the contemplated arrangement, the companies would seek to demonstrate whether computing infrastructure can operate using renewable energy generated from wave, wind and solar sources, without relying on a power connection to shore. We are working with OPT to advance the proposed collaboration toward a definitive agreement. Subject to reaching such an agreement, our next steps would focus on establishing a framework for the proposed demonstration program, including the integration of our computing assets with OPT’s offshore technology and the evaluation of technical and operational requirements.

We believe this initiative illustrates the potential to extend AI computing infrastructure beyond conventional data centers. Offshore applications could create opportunities for localized data processing in maritime monitoring, offshore energy operations, scientific research and other remote environments.

The proposed demonstration program would also evaluate potential benefits associated with offshore cooling conditions, which could help address one of the significant operating requirements of conventional computing infrastructure. These potential benefits have not yet been demonstrated and would need to be validated through testing.

The collaboration reflects our interest in pursuing innovative applications for our GPU assets and establishing relationships with companies possessing complementary infrastructure and technologies.

Building a Focused Platform for Long-Term Growth

October was an important month for Stratum Holdings. We have begun putting the core elements of our strategy in place, and our focus now shifts to converting that progress into measurable financial results.

Together, these initiatives are intended to reposition Stratum Holdings as a focused AI infrastructure company with tangible computing assets, recurring revenue potential and a leaner operating structure.

Our goal is clear: to position Stratum Holdings to achieve profitability in 2027. We believe the steps we are taking today are establishing the foundation for a stronger, more financially sustainable company.

We believe there is an opportunity to participate in the rapidly evolving AI infrastructure market, and we are working to build a scalable, revenue-generating infrastructure business with the goal of creating long-term shareholder value.

We appreciate your continued confidence and support as we execute this transformation. Our commitment is to remain focused on execution, demonstrate measurable progress and deliver on the strategic and financial objectives we have established.

We believe Stratum’s next chapter will be defined by the business we are building and the results we intend to deliver.

Sincerely,

Nicholas H. Adler
Chief Executive Officer
Stratum Holdings Corp.

About Stratum Holdings

Stratum Holdings Corp. (NASDAQ: SRTM) is an AI infrastructure company focused on GPU leasing and high-performance compute capacity. The company is transitioning from legacy real estate operations to provide scalable compute solutions supporting artificial intelligence workloads. For more information, visit www.stratumholdingscorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding Stratum Holdings Corp.’s (“Stratum” or the “Company”) strategic transformation into an AI infrastructure and high-performance computing business; the anticipated performance, utilization, revenue potential and expansion of its NVIDIA B300 GPU assets and leasing operations; the Company’s ability to establish additional commercial relationships and generate recurring revenue; the proposed divestiture of its legacy real estate businesses, including the negotiation and execution of definitive agreements, completion of the transaction, assumption of certain liabilities by the proposed buyer, anticipated reductions in operating expenses and working-capital requirements, and expected improvements in the Company’s financial position; the proposed collaboration with Ocean Power Technologies, Inc. (“OPT”), including the negotiation of definitive agreements, development and technical feasibility of offshore, renewable-powered computing infrastructure, potential operational benefits and commercial applications; the Company’s capital allocation strategy, future growth opportunities and goal of achieving profitability in 2027.

These forward-looking statements are based on management’s current expectations, estimates, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, the Company’s ability to successfully execute its strategic transformation; the performance, deployment and commercial utilization of its GPU assets; the Company’s dependence on a limited number of lessees for its GPU leasing revenue and the ability of such lessees to perform their obligations; customer demand, competitive conditions and access to capital; the ability to generate sufficient revenue and achieve profitability; the non-binding nature of the proposed real estate divestiture and OPT collaboration; the possibility that definitive agreements may not be executed within the anticipated timeframe, on the anticipated terms or at all, or that proposed transactions may not be completed; the failure to obtain required approvals, including any required stockholder approval; potential dilution from future equity issuances, including any shares issued in connection with the proposed OPT collaboration; the ability to fund, develop and successfully complete any contemplated demonstration program; risks associated with technology integration, technical performance, regulatory requirements and market adoption; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

There can be no assurance that the proposed transactions or collaborations will be completed, that anticipated financial or operational benefits will be realized, that the Company’s GPU leasing operations will generate the expected revenue, or that the Company will achieve profitability in 2027. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by applicable law.

Stratum Holdings Contact

Crescendo Communications, LLC
srtm@crescendo-ir.com | (212) 671-1020

CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) — American Lithium Minerals Inc. (OTC: AMLM) today announced the execution of a binding Farm-In Agreement with Golden Mile Resources Limited under which AMLM may earn up to an 85% interest in Exploration License E57/1043, located in the prospective Youanmi Gold Project region of Western Australia.

The agreement provides AMLM with exclusive exploration rights over the tenement and a structured pathway to majority ownership through staged exploration expenditures.

Under the terms of the agreement, AMLM may earn an initial 51% interest by funding A$500,000 in exploration expenditures, consisting of an initial A$100,000 commitment followed by an additional A$400,000 of qualifying exploration activities within three years of the commencement date. Upon completion of these expenditures, AMLM will be entitled to receive a 51% interest in the tenement. AMLM may earn an additional 34% interest, increasing its ownership to 85%, by funding a further A$500,000 in exploration expenditure within five years of commencement date.

The agreement is subject to a condition precedent requiring Golden Mile Resources Limited to obtain regulatory exemptions related to the extension of the term of Exploration License E57/1043. Following satisfaction of this condition, AMLM intends to commence a comprehensive exploration program focused on evaluating the property’s gold potential.

Management Commentary

Frank Kristan, Director and Secretary of American Lithium Minerals, commented:

“This transaction represents a significant step forward in AMLM’s strategy of acquiring and advancing high-quality mineral assets in premier mining jurisdictions. The Yuinmery Project provides an opportunity to secure a controlling interest in a highly prospective exploration property in Western Australia, one of the world’s leading mining regions. We believe this agreement positions AMLM to create substantial shareholder value through systematic exploration and potential resource development.”

About American Lithium Minerals, Inc.

American Lithium Minerals, Inc. (OTC: AMLM) is a multi-commodity critical minerals exploration company headquartered in Carson City, Nevada. The Company holds active project interests in gold, silver, copper, lithium, and rare earth elements across Nevada (USA), Chile, British Columbia, Yukon and Quebec (Canada), and Western Australia. AMLM’s portfolio includes 11 active project interests, including the Higginsville gold project in Western Australia, silver and copper exploration in Chile, rare earth interests in Quebec, and lithium properties in Nevada.( www.americanmineralresources.com)

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results. Such statements involve a number of risks and uncertainties, including, without limitation, statements regarding the Company’s strategic initiatives, project development plans, expected commodity exposure, anticipated market conditions, the strength of macro tailwinds across critical minerals sectors, and the Company’s ability to advance its multi-commodity portfolio.

Investor Contact

American Lithium Minerals, Inc.
1007 South Street
Carson City, Nevada 89701
Telephone: (775) 587-6137
Email: info@americanmineralresources.com
Website: www.americanmineralresources.com
X / Twitter: American Mineral Resources (OTCID:AMLM) (@AMR_MineralRes) / X
LinkedIn: linkedin.com/company/american-mineral-resources

WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company’s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting^® 2026, taking place Nov. 5–9, 2026, at the Colorado Convention Center in Denver, Colorado.

As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-naïve and treatment-experienced patients. These findings will also be available as a companion e-poster via the AASLD website.

Additionally, Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., will present a poster on molybdenum balance in patients treated with ALXN1840.

Presentation Details

Oral Presentation

Title: Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial
Presenter: Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program, University of Michigan Health System
Session: Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
Publication Number: 0198
Date and Time: Sunday, Nov. 8, 2026, 12:15 p.m. to 12:30 p.m. MT

Companion E-Poster

Availability: An e-poster of the oral presentation will be available via the AASLD website. 

Poster Presentation

Title: Neutral Molybdenum Balance and Lack of Molybdenum Toxicity in Subjects Treated with Tiomolibdate Choline Supports Safety Profile of TMC
Presenter: Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Consultant Hepatologist, Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London
Session: Poster Session I: Metabolic and Genetic Disease
Publication Number: 1420
Date and Time: Thursday, Nov. 5, 2026, 12:00 p.m. to 1:00 p.m. MT

The abstracts are available on the AASLD conference website. Presentation materials will be made available in the Investors section of Monopar’s website at www.monopartx.com following each presentation.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body’s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the regulatory and approval process for ALXN1840, and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:
X: @MonoparTx | LinkedIn: Monopar Therapeutics

Vancouver, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB10; OTCQB:TEBAF) is pleased to announce that Terra North Resources Corp. (“Terra North”), in which Terra owns 34.7% equity, has received the final dataset from an airborne survey conducted over it mineral exploration claim immediately east of Fontaine Lake located ca. 55 km north-northeast of Stony Rapids, Saskatchewan. The results outlined below follow those gathered from the Charlot-Neely Lake survey (see the Company’s news release dated October 27^th, 2026).

Terra North holds an option to acquire 100% interest in the Project from Fulcrum Metals Canada Ltd. subject to satisfying certain earn-in requirements (see the Company’s news release dated July 3^rd, 2024).

Highlights

• Eight (high confidence) uranium target zones have been identified over the Fontaine Lake claim characterized by clustering of strong, statistically significant uranium peaks;

• Uranium anomalies chiefly align with the NE-SW trending Grease River Shear Zone and corroborate previous ground findings while thorium/(REE) enrich zones dominate the SW and SE margins of the claim area due to lithological and structural controls, respectively;

• Coinciding thorium and potassium anomalies in the SW and SE domains transitioning into localized U-dominant hotspot clusters along structural splays are potentially indicative of felsic gneiss / pegmatite margin Rössing-style and polymetallic REE-U mineralization.

Terra Balcanica and Terra North CEO, Dr. Aleksandar (Alex) Mišković, commented: “Our airborne geophysics program continues uninterruptedly and after the very encouraging results from the Beaverlodge district, Terra North has now defined some exceptional uranium targets over its Fontaine Lake claim as well. We are keen to ground truth the findings in the context of the legacy targets identified by Fulcrum’s 2023 field work although the Grease River Fault already appears to be the principal zone of interest with half a dozen U anomalies detected within the claim. We shall also focus on two zones of strong thorium anomalism along the claim margins.”

Survey Parameters
The 1,400.4-line km survey across 59.86 km² of the Fontaine Lake claims was conducted at 50-metre line spacing along 91° of azimuth with 500-m spaced, N-S oriented tie lines. A16-detector, thermally stabilized, Compton shielded, NaI gamma ray spectrometer mounted on a Cessna A185F Skywagon that flew as a tight drape at the speed of 95-110 knots was operated simultaneously with a Scintrex CS-III magnetometer, sampling at 1,000 Hz to generate detailed maps of magnetic susceptibilities and radioactivity (Figures 1 through 3).

Fontain Lake Geology and GRSZ
The Fontaine Lake claim features the high-grade metamorphic rocks of the Rae Province near the Tantato-Zemlak domain margins and overlaps the Grease River Shear Zone (“GRSZ”) corridor. It is known to contain multiple high radioactivity zones and carries a high potential for intrusive and pegmatite-hosted uranium mineralization. Historic rock chip assays have locally yielded up to 1.4% U₃O₈. The area is also prospective for REE mineralization given extensive lake sediment anomalies defined along its eastern and NW edge. Historically, minimal exploration program was completed on this claim by CanAlaska in 2008 whose geologists recommended further work.

The principal structural characteristic of Terra North’s Fontain Lake claim is the Grease River Shear Zone, a major, deep-seated regional tectonic boundary. It separates the Paleoproterozoic Beaverlodge tectonic domain to the northwest from the highly deformed Tantato domain, a part of the East Athabasca mylonite triangle, to the southeast. The GRSZ strikes NNE-SSW and cuts diagonally upward through the east-central sector of the exploration claim. It exits toward the top-right corner of the claim as it continues onward toward Selwyn Lake. The GRSZ is a prominent strike-slip brittle-ductile shear zone. It accommodates deep-crustal deformation that was later reactivated during intraplate tectonic events ca. 1.9 to 1.8 billion years ago during the Trans-Hudson Orogeny. The mylonitic rocks making up the northeastern continuation of the shear zone extend well into the backcountry, striking along areas like the southern shore of Selwyn Lake near the border with Northwest Territories. As a major crustal shear, GRSZ provides an excellent conduit for U-bearing fluids along the northern margin of the Athabasca Basin. Intersections with conjugate structures and its splays have shown to host the “Beaverlodge-style” uranium vein occurrences within Fontain Lake area. Currently active exploration properties flanking this structure include the Eagle Plains Shasko Bay Project and SKRR Exploration’s Father Lake project aimed at identifying uranium structural traps.

Fontaine Lake Results: Radiometrics
The dominant NNE–SSW trending GRSZ appears to act as the primary regional plumbing system, focusing hydrothermal uranium mineralization into structural traps as evidenced by the dense cluster of high-grade U₃O₈ assays and multi-element hotspots aligned along this corridor ( Figure 1b and 2). These anomalies represent the best ground targets to follow up on.

On the Total Count and Ternary maps (Figure 1a and 2), the strong WNW–ESE linear trends manifest as sharp, dark or subdued troughs running parallel to the high-amplitude magnetic dykes. Because diabase is relatively non-radioactive compared to felsic country rocks, these massive dykes create a distinct spectral “shadow” or linear dampening effect in total counts.

The prominent thorium anomalies concentrated in the SW and SE corners of the survey area (blue circles in Figure 2) reflect a fundamental geochemical contrast between its inert nature and hydrothermally mobile uranium. Thorium is an immobile lithophile element and is not readily dissolved by low-temperature hydrothermal fluids. Uranium, however, is easily oxidized and mobilized by hydrothermal fluids, allowing it to be stripped from source rocks and focused structurally along active conduits like the NNE–SSW Grease Fault Shear Zone.

Click here to view image

Click here to view image

Figure 1. Total gamma-ray radiation counts of the Fontaine Lake claim (above) reveal linear, NNE-SSW airborne radiometric anomalies with up to 3,000 cps dominating southern and western parts of the ca. 60 km² are. The U map of the Fontaine Lake claim (below) reveals anomalous zones proximal to the trace of the Grease River Shera Zone (yellow line) as well as a  cluster in the northwesternmost corner of the claim.

Alternatively, the strong thorium and REE signatures indicate that the SW and SE structural blocks contain a high density of thorium- and rare-earth-enriched pegmatites, leucogranites, or anatectic granitic melts. These lithologies represent fertile plutons of the high-grade Tantato Domain basement that is naturally enriched in Th and REEs.

While the NNE–SSW Grease Fault Shear Zone controls the epigenetic, structurally hosted uranium mineralization, the Th anomalies map out the thorium- and REE-bearing pegmatitic and granitic source rocks sitting outside the main shear corridor.

Click here to view image

Figure 2. Ternary radiometric map of the Fontaine Lake claims combines the relative abundances of potassium (K %-red), uranium (U ppm-green), and thorium (Th ppm-blue) with airborne gamma-ray spectrometer anomalies as candidate U and Th showings. Also shown are the historic U showings. Three domains are noticeable: a) magenta/pink Domains (high K+Th, low U) representing unaltered to weakly altered basement rocks (felsic gneisses, granites, and pegmatites), b) bright green domains (high U relative to K+Th) are characterized by uranium enrichment zones (hydrothermal mobilization or pitchblende-rich horizons), while c) blue domains (high Th) are dominated by heavy-mineral/thorite-bearing, resistant units or thorium-rich intrusive phases. Black corridors signal attenuation either over lakes (e.g., Eddie Lake), or thick glaciofluvial overburden. The Grease River Fault Zone is demarcated by NNE-SSW trending white line. Also shown are assay and ground radiometrics results from the 2023 field season. Uranium anomaly candidates are detected and graded by: i) background removal, ii) candidate testing (total counts exceed a floor and U rises a set number of standard deviations (z-score) above  rolling background, by an absolute min. ppm margin), iii) grading (strength of the coincident total-count peak and K/Th purity), and iv) peak deduplication (adjacent samples of one anomaly are collapsed to a single peak). By overlaying automated hotspot anomaly symbols (classified by confidence grades and element channels), the map becomes the ultimate diagnostic tool for distinguishing primary host-rock lithology from hydrothermal alteration and uranium enrichment.

Fontaine Lake Results: Magnetics
Lithologically, the prominent, linear to arcuate belts of high magnetic intensity running across the southwestern and northeastern sectors of the survey block reflect magnetite-rich lithologies. These typically correspond to mafic granulites, amphibolites, mafic intrusive sills, or iron-formation bands intercalated within felsic gneiss sequences. The middle portion of the survey block is characterized by a broad, subdued magnetic low (Figure 3a). This likely represents a thick panel of felsic to intermediate quartz-feldspathic gneisses, granitoid plutons, or metasedimentary rocks with low modal magnetite content.

Click here to view image

Click here to view image

Click here to view image

Click here to view image

Figure 3. a) Levelled and decorrugated Total Magnetic Intensity (TMI) map (above) shows the broad distribution of near-surface and deep crustal magnetic susceptibility. Reds and pinks represent mafic/ultramafic intrusives, iron formations, and gneisses with high magnetite or pyrrhotite content while blues reflect felsic plutons, quartzites, or metasediments; b) the First Vertical Derivative (1VD) map of the Fontaine Lake claims (below) enhances shallow geological sources and sharpens magnetic anomalies by removing regional long-wavelength trends as it highlights the edges and boundaries of magnetic lithologies; c) Tilt Derivative (TDR) normalizes amplitudes to emphasize both shallow and deep magnetic edges, with its zero-contour tracking directly over steep geological contacts (faults or intrusive margins), while d) the Total Horizontal Gradient (THG) measures the maximum rate of horizontal change in the magnetic field, directly mapping the location of geological contacts and fault/shear boundaries.

The 1VD map (Figure 3b) breaks down the broad magnetic highs into sharp, narrow stratigraphic panels, highlighting tight folding, transposition, and compositional layering sub-parallel to the regional northwest-southeast Mackenize dyke swarm (Figure 3b).

Structurally, the most striking features on the TDR & THG maps (Figure 3c and 3d) are the high-amplitude, WNW–ESE to NW–SE trending linear anomalies representing Proterozoic Mackenzie diabase  dykes. The dykes preferentially fill ancient, deep-seated crustal-scale extension fractures and map out the Proterozoic extensional stress field that affected the Rae Province ca. 1.27 billion years ago. These continuous magnetic highs display sharp inflection points and steep gradients on the THG and TDR maps, indicative of major ductile-to-brittle shear zones similar in style to GRSZ. While the dykes themselves are impermeable, their chilled margins and thermal aureoles, as well as any post-emplacement reactivation along the dyke contacts, frequently function as zones of weakness and can localize later (U-bearing) hydrothermal fluids. The Tilt Derivative (TDR) map (Figure 3c) acts as an exceptional edge detector, revealing a dense secondary network of cross-cutting brittle fractures and minor fault splays oriented at high angles to the primary WNW–ESE dike fabric. Truncations, bends and offsets of the dykes (magnetic highs) visible in the 1VD and THG maps point to multiphase deformation, including late-stage brittle fault reactivation that disrupted the older metamorphic fabric. These structural jogs, bends, and cross-cutting offsets are prime candidates for sites of fluid mixing and mineral precipitation.

Summary
The key uranium exploration targets fall into three distinct structural and lithological archetypes:

1. The Grease River Shear Zone (GRSZ) and splays (basement-hosted uranium)
High-density clusters of Grade-1 hotspot anomalies associated with extreme surface radiometrics (up to 53,000 cps) and high-grade surface rock samples (1.08% and 1.44% ) confirm active fluid transport and structural trapping of pitchblende/uranium mineralization along this shear trend. This forms the highest priority for trenching, channel sampling, and drill testing.

2. Shear Zone – Mackenzie Dyke Intersections (Dilatant & Rheological Traps)
Intersections where the WNW–ESE linear magnetic highs (Mackenzie dykes) are cross-cut or truncated by the GRSZ lineaments can serve as rheological traps due to intense mechanical contrast between rigid diabase dykes and surrounding felsic gneisses with localized brittle fracturing, fault breccias, and dilatant jogs appearing during shearing. Iron-rich Fe²⁺ mafic dyke margins may provide a reducing environment, forcing dissolved U⁶⁺ in ascending hydrothermal fluids to precipitate as pitchblende. This is highlighted by anomalous surface samples with 0.11% U₃O₈ and 1351 ppm Nb situated at structural/dyke contacts in the northeast sector of the claim.

3. Felsic Gneiss / Pegmatite Margin Targets (Rössing-Style & Poly-Metallic REE-U)
Coinciding Th and K anomalies in the SW/SE domains transition into U-dominant hotspot clusters along structural splays might be indicative of high-grade, poly-metallic mineralization where basement-hosted intrusive pegmatites and granites undergo hydrothermal overprinting. Surface assays in these transitional structural settings yield combined high-grade uranium and rare earth anomalies, such as 0.81% U₃O₈ with 4732 ppm TREE and distinct REE lake sediment trends.

Qualified Person
Dr. Aleksandar Mišković, P.Geo, is the Company’s CEO and designated Qualified Person within the meaning of National Instrument 43-101 Standards of Disclosure of Mineral Projects (“NI 43-101”). Dr. Mišković has prepared this news release and validated that the information contained within is factual and accurate.

About the Company
Terra Balcanica is a polymetallic exploration company targeting large-scale mineral systems in southeastern Europe. The Company has 100% interest in the Viogor Project in eastern Bosnia and Herzegovina. Terra holds a 34.7% ownership in Terra North Resources Corp. and its Canadian assets that comprise a 100% optioned portfolio surrounding the world-renowned Athabasca basin. The Company emphasizes responsible engagement with local communities and stakeholders. It is committed to proactively implementing Good International Industry Practice (GIIP) and sustainable health, safety, and environmental management.

ON BEHALF OF THE BOARD OF DIRECTORS

Terra Balcanica Resources Corp.
“Aleksandar Mišković” 
Aleksandar Mišković
President and CEO

For the complete information on this news release, please contact Aleksandar Mišković at amiskovic@terrabalcanica.com, +1 (514) 796-7577, or visit www.terrabalcanica.com/en/news.

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the words “will”, “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, the terms and completion of the Private Placement, the anticipated Closing Date, the payment of finder’s fees and the use of proceeds for the Private Placement and the completion of a going-public transaction by Terra North. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These forward-looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to, the ability to obtain regulatory approval for the Private Placement; the state of the equity financing markets in Canada and other jurisdictions; volatility and sensitivity to market prices; volatility and sensitivity to capital market fluctuations; and fluctuations in metal prices. Such forward-looking statements should not be unduly relied upon. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone. 

GAMEFILM data highlight high prevalence of heart disease in retired NFL players, underscoring need for advanced plaque assessment

SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced prospective clinical outcomes from the DECIDE registry will be presented at the American Heart Association (AHA) Scientific Sessions 2026. In an evaluation of more than 6,000 well-matched patients, Heartflow Plaque Analysis with Plaque Staging demonstrated a 34% reduction in major cardiovascular disease (CVD) events and half the rate of myocardial infarction (MI) at one year compared to coronary computed tomography angiography (CCTA) alone.

The significant reduction in major CVD events stemmed from meaningful shifts in patient care. By quantifying total plaque volume and staging disease severity, the platform equipped clinicians to optimize drug regimens earlier, driving a 41% early increase in patients achieving low-density lipoprotein cholesterol (LDL-C) goal, as compared to CCTA alone.

“The DECIDE registry answers the core questions in preventive cardiology: Does AI-powered coronary plaque analysis guide medical therapy? Does it empower patients to achieve target lipid goals? And ultimately, does it reduce major CVD events?” said Leslee Shaw, Ph.D., Director of the Blavatnik Family Research Institute at the Icahn School of Medicine at Mount Sinai, New York, and co-lead investigator of the DECIDE Registry. “The one-year findings demonstrate that Heartflow Plaque Analysis provides clinicians with the objective data needed to optimize preventive care earlier and with greater precision, while significantly reducing major CVD events and heart attacks compared to CCTA alone. By directly linking this non-invasive approach to targeted lipid lowering, it helps bridge diagnostic imaging with meaningful risk reduction in everyday practice.”

DECIDE Registry: Transforming Plaque Quantification into Preventive Outcomes
Moderated Digital 21, Nov. 9, 11:06 a.m. CT

Key DECIDE findings regarding use of Heartflow Plaque Analysis:

• 34% fewer major CVD events (cardiovascular death, MI, revascularization or stroke) vs. CCTA alone and half the rate of MI over the first year.
• Management changed in >50% of patients by 90 days.
• 50% reached target LDL-C (<70 mg/dL) by 90 days vs. 35% with CCTA alone, sustained through one year.
• 18.7 mg/dL average LDL-C reduction at 90 days with a management change, sustained at one year.

GAMEFILM: Heartflow AI Uncovers Hidden Heart Disease in 85% of Retired NFL Players
Moderated Digital 22, Nov. 9, 9:15 a.m. CT

Heartflow will also present findings from its groundbreaking GAMEFILM registry evaluating coronary artery disease in former professional athletes. Despite their history of elite physical conditioning, former football players often face long-term cardiac risks that standard visual tests can miss, with studies showing up to one in three former National Football League (NFL) players die from cardiovascular disease.¹

The registry evaluated CAD in 200 retired NFL players using CCTA paired with Heartflow Plaque Analysis. Although fewer than 10% reported exertional symptoms (chest pain or dyspnea), quantitative plaque analysis revealed a high prevalence of hidden disease:

• Detectable coronary plaque was present in 85% of the former NFL players, despite only 13% having a prior CAD diagnosis.
• On average, nearly 90% of the detected plaque was soft (non-calcified), which is associated with higher disease risk than calcified plaque and cannot be detected by traditional coronary artery calcium scores.
• 42% of former players had obstructive CAD (>50% stenosis), 33% had severe or extensive plaque burden, and 29% had functionally significant ischemia.
• Retired linemen exhibited much higher plaque volumes for their age than non-linemen (63.3rd vs. 31.9th percentile).
• 88% of players not currently on lipid-lowering therapy expressed willingness to initiate treatment following review of their AI plaque analysis results with a physician.

“Many former players are surprised to learn that even after years of elite training and staying active, coronary artery disease can be quietly building in their arteries, and it remains their greatest long-term health threat,” said Yiannis Chatzizisis, M.D., Ph.D., Professor of Cardiology and Chief of the Cardiovascular Division at the University of Miami Miller School of Medicine, and GAMEFILM investigator. “When these former NFL players could see the precise volume and type of plaque in their own arteries with Heartflow Plaque Analysis, nearly 9 in 10 of those not on cholesterol-lowering therapy said they were ready to begin treatment. GAMEFILM is helping us understand the burden of disease in former professional athletes and giving them personalized insights to act on their heart health while there’s still time to make a difference with medication and lifestyle changes.”

Building on its success enrolling retired players from the NFL, National Basketball Association (NBA) and National Hockey League (NHL), the GAMEFILM registry has now expanded to include former players from Major League Baseball (MLB), as well as professional staff from these leagues and U.S. college sports teams. This expansion broadens Heartflow’s initiative to evaluate hidden cardiovascular risk and support proactive, long-term disease management of former professional athletes across major sports.

“Achieving faster, durable lipid control is a vital goal, and seeing that translate into a 34% reduction in one-year major CVD events in the DECIDE data is extraordinary,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer at Heartflow. “From the more than 6,000-patient DECIDE registry to our GAMEFILM registry, the data being presented at AHA prove that Heartflow Plaque Analysis goes beyond detecting disease to altering patient trajectories and connecting non-invasive precision to proactive, life-saving prevention.”

Experience Heartflow Plaque Analysis with Plaque Staging at AHA 2026

AHA 2026 attendees are invited to visit Heartflow at exhibit booth #711 for live demonstrations of Heartflow Plaque Analysis and Heartflow FFR_CT Analysis. See the full schedule of other Heartflow programs, including an expert theater, simulation zone, and more at event.heartflow.com/aha2026.

About Heartflow Plaque Analysis with Plaque Staging

Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque analysis tool with 95% agreement against the gold standard, intravascular ultrasound (IVUS), in a prospective, international trial.² Heartflow Plaque Staging builds on this foundation, categorizing plaque burden into clinical risk stages to guide actionable risk stratification.^3,4 The framework is validated in 23,000 patients with up to 16 years of follow-up, offering the reproducibility clinicians need for serial monitoring and individualized preventive care.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision diagnostic testing and management for coronary artery disease (CAD) through clinically proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 625 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 750,000 patients worldwide.⁵ Key benefits include:

• Unmatched proprietary data pipeline: Built from the world’s largest database of more than 200 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible diagnostic insights across diverse patient populations.
• Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Heartflow is the only AI platform prospectively validated against invasive gold standards and demonstrated through real-world evidence to improve patient outcomes.^3,6,7,8 Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
• Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
• Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST r2, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Media Contact
Elliot Levy
elevy@heartflow.com

Investor Contact
Nick Laudico
nlaudico@heartflow.com

^{________________________________
1} Venkataramani AS, Gandhavadi M, Jena AB. Association between playing American football… JAMA. 2018;319:800–806. https://doi.org/10.1001/jama.2018.0140
² Ihdayhid A, et al. Radiol Cardiothorac Imaging. 2024. doi: 10.1148/ryct.230312 and internal bridging study with ICC correlation between first generation and second generation Plaque Analysis algorithm.
³ Rinehart, et al. JACC Imaging. 2025.
⁴ Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI)
⁵ Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454.
⁶ Narula, et al. EHJ CVI 2024.
⁷ Danad, et al. JAMA Cardiol 2017.
⁸ Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024. (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years).

The study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementias

FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX: NHLTY, NGHLF) today announced the launch of the UK Biobank vanguard study to measure blood-based biomarkers that are of particular importance for neurodegenerative disease. The UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife (UKB-PRISM) study will be conducted in Nightingale’s laboratories using Alamar’s NULISA platform, which is purpose-built to detect low-abundance proteins at a sensitivity not previously achievable at scale, and will measure hundreds of circulating protein biomarkers in 80,000 blood samples from UK Biobank participants. Findings will create one of the world’s largest open-access resources for understanding the early molecular indicators of neurodegeneration.

“Understanding how the brain stays healthy as we age is one of the biggest challenges in medical research,” said Dr. Adam Lewandowski, deputy chief scientist at UK Biobank. “Proteins play a vital role in this process, helping to repair tissue, regulate inflammation and support countless functions throughout the body. Yet we still know relatively little about how they work together to influence brain health. Made possible by the generosity of our participants, these new data will provide an invaluable snapshot of the proteins associated with brain health decades before conditions such as dementia and Parkinson’s disease are diagnosed.”

Neurodegenerative disease represents one of medicine’s most urgent unmet needs. Alzheimer’s disease and other forms of dementia affect more than 55 million people globally and are on track to nearly triple by 2050. Parkinson’s disease, the world’s fastest-growing neurological disorder, affects more than 12 million people today and is projected to exceed 25 million by 2050. In both diseases, biological changes may begin years before diagnosis. By measuring proteins of individuals long before symptoms emerge, this study creates a rare opportunity to understand Alzheimer’s and Parkinson’s as overlapping conditions with shared biological roots and to identify the earliest molecular signals when intervention is still possible.

“For decades, the earliest biology of neurodegeneration has been out of reach in blood because the proteins that matter most are present in such small amounts. NULISA was designed to change that,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Working with Nightingale and UK Biobank, we can now measure those signals across tens of thousands of people, years before symptoms appear, and give researchers everywhere a new way to ask when and why these diseases begin.”

“This study reflects what Nightingale has built: a laboratory platform that delivers high-quality blood biomarker data at population scale. We have already generated metabolomic data on all 500,000 UK Biobank participants, and adding brain health protein biomarkers measured in our laboratories to the same cohort creates a uniquely rich resource for understanding the earliest molecular changes behind dementia, Parkinson’s disease and related conditions. Identifying disease risk years before symptoms appear is the foundation of preventive healthcare, and studies like this show it can be done at the scale that real impact requires,” said Teemu Suna, founder and CEO of Nightingale Health.

The study is funded by Alzheimer’s Research UK, LifeArc, and other funding partners, and is expected to be completed by the end of 2027. Combined with UK Biobank’s uniquely rich imaging, genetic, metabolomic and lifestyle data, these new data will create a powerful resource for researchers worldwide, helping to unlock discoveries that could lead to earlier detection and better treatments for these conditions. Following its completion, the full dataset will be made available to approved researchers worldwide through the UK Biobank Research Analysis Platform.

“The scale of this study, combined with the cutting-edge technologies being used, has the potential to transform our understanding of how dementia starts and progresses,” said Dr. Sheona Scales, director of research at Alzheimer’s Research UK. “Understanding the biological changes that underpin Alzheimer’s disease is essential to developing treatments that can slow or stop its progression. We’re excited by the potential of this study to pave the way for earlier diagnosis and more effective treatments.”

“Rare dementias can be particularly difficult to diagnose, with symptoms that overlap with other conditions and clues that may only become clear when different kinds of health data are brought together,” said Sam Barrell, CEO of LifeArc. “By combining large-scale protein measurements with UK Biobank’s extensive health data, this study will give researchers a valuable resource to investigate the biological changes behind neurodegenerative diseases, including rare dementias. This could help build a better understanding of these conditions and lay the groundwork for more accurate diagnosis in the future.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

About Nightingale Health
Nightingale Health’s technology is validated in over 1,000 peer-reviewed scientific publications and is used in many of the world’s leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 250,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company’s Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more at nightingalehealth.com.

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ ability to unlock high-quality multiplexed proteomic data from remotely collected samples. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Alamar Biosciences Media Contact: 
Media@alamarbio.com 

Alamar Biosciences Investor Contact: 
Investors@alamarbio.com 

Nightingale Contact:
Teemu Suna, CEO
ir@nightingalehealth.com

FORT MILL, S.C., Nov. 02, 2026 (GLOBE NEWSWIRE) — Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced that its VIVO system has received FDA 510(k) clearance for expanded labeling in its Indications for Use statement.

The VIVO system is now cleared for a broader patient population, specifically individuals with structural heart disease (SHD) who are undergoing catheter ablation for monomorphic ventricular tachycardia (VT).

Structural Heart Disease (SHD) involves damaged, scarred, or enlarged heart tissue that disrupts the heart’s natural electrical pathways. This structural damage frequently triggers severe arrhythmias, such as Ventricular Tachycardia (VT). While standard care relies heavily on implantable defibrillators and medications, catheter ablation remains underutilized due to long procedural times and inconsistent outcomes.

“This expanded U.S. labeling for VIVO is another milestone in delivering enhanced ablation strategies,” said David Jenkins, CEO of Catheter Precision. “Our clinical data demonstrates that VIVO maintains the same high standards of accuracy and safety in patients with structural heart disease as it does in those without it. Ventricular ablations are inherently complex, but SHD cases present unique challenges because every patient’s anatomy is different. By enabling physicians to visualize a patient’s specific anatomy ahead of time, VIVO improves pre-procedural planning, which can reduce overall procedure times and optimize patient outcomes.”

About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias prior to an electrophysiology procedure, potentially streamlining procedural workflow. VIVO has received marketing clearance from the U.S. FDA and carries the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

About Flyte Aviation, Inc.
Flyte Aviation, Inc. is a holding company for Fly Flyte and Ponderosa Air. Fly Flyte is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the United States and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC, Flyte is delivering a faster, safer and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
IR@FlyFlyte.com

(800) 763-0904

Company adds 5,336 SOL, bringing total treasury holdings to 2,600,948 SOL and SOL equivalents

CHAD’s new 14.00% annual dividend rate takes effect today, offering investors one of the highest yields in digital credit

BOCA RATON, FL, Nov. 02, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that its total holdings of SOL and SOL equivalents increased by 5,336 SOL since its last update, bringing its treasury to approximately 2,600,948 SOL, up from 2,595,612 SOL.

The Company continues to accumulate SOL as adoption of the Solana network expands, particularly in tokenized equities and other real-world assets.

Tokenization Momentum Continues
The Company remains particularly bullish on tokenization as a long-term driver of Solana adoption. According to data from RWA.xyz, the total value of tokenized real-world assets (“RWAs”) on Solana recently surpassed $5 billion for the first time, reaching approximately $5.1 billion in late October. The milestone reflects accelerating adoption of Solana as infrastructure for traditional financial assets, including tokenized equities, U.S. Treasuries, private credit, and other real-world assets.

The Company believes the continued migration of traditional financial assets onchain represents one of the largest long-term opportunities in digital assets. Solana’s speed, low transaction costs, and expanding institutional ecosystem position the network to capture a meaningful share of this rapidly growing market.

“Tokenization is rapidly moving from an emerging use case to a major driver of blockchain adoption,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “With more than $5 billion in real-world assets now on Solana, we’re seeing traditional finance increasingly embrace the network. We believe this is just the beginning of a much larger shift in how financial assets are issued, traded, and settled. Tokenization will be a massive long-term tailwind for SOL, and we’re continuing to accumulate accordingly.”

CHAD’s New 14% Dividend Rate Takes Effect Today
Effective today, November 2, 2026, the annual dividend rate on the Company’s Variable Rate Series C Perpetual Preferred Stock (Nasdaq: CHAD) has increased from 13.00% to 14.00%, making CHAD the highest-yielding variable-rate digital credit security in the market.

At its $10.00 stated amount, CHAD’s new annual dividend rate equates to $1.40 per share, with cumulative dividends payable each business day when declared.

CHAD offers income-focused investors a differentiated way to participate in the Company’s SOL treasury strategy. Unlike traditional corporate treasuries, which typically hold cash and other low-yielding assets, DeFi Development Corp.’s SOL holdings can generate recurring income through native staking and validator operations. The Company believes this productive treasury creates an attractive foundation for its digital credit offerings.

“Solana’s native yield means our treasury is always working,” added Onorati. “With CHAD now offering a 14% dividend rate, we’re bringing that productivity to income investors in a way that makes their money work harder. We believe CHAD is among the most compelling income opportunities in digital credit today.”

The Company intends to continue growing CHAD as a core component of its long-term capital strategy, providing income-focused investors with an alternative to common equity while supporting continued SOL accumulation.

Learn more about CHAD at www.defidevcorp.com/chad.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding SOL per share growth; future SOL holdings; anticipated changes in borrowings and liquidity; future SOL accumulation and per-share accretion; future adoption of Solana, tokenized assets and stablecoins; capital raising and deployment; the anticipated issuance price of shares under the CHAD ATM program; future CHAD dividend rates and the declaration and payment of CHAD dividends; the intended use of proceeds; and the Company’s ability to expand its SOL treasury and increase revenue. These statements can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure of demand for SOL, or activity on the Solana network, to continue to develop and grow as we anticipate or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment, including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth; (xi) risks relating to CHAD, including that the dividend rate may be adjusted, that dividends are payable only when declared, that CHAD may trade below its stated amount, that the trading price of CHAD may be volatile, that the Company may be unable to sell CHAD under the CHAD ATM at or above its stated amount, and that staking and validator rewards may be insufficient to support dividend payments; and (xii) other risks and uncertainties more fully described in the sections captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, the prospectus supplement for the CHAD ATM and other reports we file with the SEC.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this press release are made as of its date, and the Company undertakes no duty to update such information except as required under applicable law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Offers and sales of CHAD under the CHAD ATM are made only by means of the prospectus supplement and accompanying prospectus forming part of the Company’s effective shelf registration statement on Form S-3 filed with the SEC.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

China Resources Medical Devices to serve as exclusive distributor for Baird’s microwave ablation (MWA) products in 19 markets in the PRC

Agreement includes initial purchase order of RMB 6 million ($900,000)

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a global leader in microwave ablation (MWA) technology, today announced that its PRC subsidiary, Nanjing Changcheng Medical Equipment Company Limited, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. (“China Resources Medical Devices”), a subsidiary of China Resources Pharmaceutical Group Limited (Stock Code: 03320.HK).

Under the agreement, China Resources Medical Devices will serve as the exclusive distributor for Baird’s specified MWA products in 19 key markets in the People’s Republic of China, with a focus on regions where Baird has historically had a limited direct commercial presence. On execution of the agreement, China Resources Medical Devices placed an initial order totaling approximately RMB 6 million ($900,000).

“This partnership with China Resources Medical Devices, one of the leading medical technology distributors in the PRC, provides another important validation of our technology. It will further strengthen our leadership position in China and help accelerate access to hospitals in previously untapped regions,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “With their extensive distribution network and nationwide prominence, we believe that adding our products to China Resources’ portfolio could help drive further adoption of our MWA technology throughout the country. We remain committed to growing our business in the Chinese market, and expect that this agreement will play an important role in achieving this goal while we continue to expand in other key global markets, including the U.S.”

With an established leadership position in the PRC market, Baird Medical is working to further expand the penetration of its technologies in the region, while growing its presence in other established markets including the United States where the Company began accelerating the build-out of its commercial infrastructure in late-2025. In addition to its expansion in the U.S. and PRC, Baird Medical continues to broaden its international commercial footprint across markets including Argentina, Vietnam, Indonesia, and Pakistan, with regulatory initiatives underway in additional geographies.

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

About China Resources Pharmaceutical Group

China Resources Pharmaceutical Group Limited (CR Pharmaceutical; Stock Code: 03320.HK) is a leading integrated pharmaceutical company in China. As part of the China Resources Group, it engages in R&D, manufacturing, distribution, and retail of medical and health products, featuring well-known brands like CR Sanjiu, CR Double-Crane, CR Jiangzhong, and Dong-E-E-Jiao. The company focuses on delivering quality healthcare solutions. Visit the CR Pharmaceutical Official Website for more details.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled “Risk Factors” therein, and in ExcelFin’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin’s most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com